| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | CLIQ Digital - Increased churn weakens FY24 outlook | 519 | Edison Investment Research | CLIQ Digital delivered a disappointing start to FY24 in Q124, as its membership base fell following a change in refund programmes from credit card providers, making it easier for subscribers to cancel.... ► Artikel lesen | |
| 14.05. | Greggs - Encouraging start to FY24 | 256 | Edison Investment Research | Greggs' trading update for the first 19 weeks of the year shows that the company is driving superior revenue growth from its key initiatives of growing space, delivery and evening sales and leveraging... ► Artikel lesen | |
| 14.05. | Finsbury Growth & Income Trust - Train puts his money where his mouth is | 327 | Edison Investment Research | Finsbury Growth & Income Trust (FGT) has been managed by Lindsell Train since the beginning of 2001. During his long tenure, approaching a quarter of a century, lead manager Nick Train has steadily... ► Artikel lesen | |
| 14.05. | Baker Steel Resources Trust - Potential to generate a 20%+ yield | 294 | Edison Investment Research | Baker Steel Resources Trust (BSRT) offers the potential for regular dividend and royalty income, as well as realisation proceeds, from its maturing portfolio of natural resources companies. Despite... ► Artikel lesen | |
| 14.05. | Pan American Silver - A taste of things to come | 979 | Edison Investment Research | Pan American Silver (PAAS) has seen an encouraging start to the year with Q124 silver and gold production in line with management expectations and costs for both segments below its quarterly guidance.... ► Artikel lesen | |
| 14.05. | JDC Group - Well on track in 2024 | 410 | Edison Investment Research | JDC Group (JDC) reported strong Q124 results. Revenue growth accelerated to 21.6% from 10% in FY23, driven by its Advisortech division (+22.6%). In terms of profitability, the EBITDA margin increased... ► Artikel lesen | |
| 14.05. | Newron Pharmaceuticals - Evenamide potential for treatment of schizophrenia | 439 | Edison Investment Research | Newron Pharmaceuticals has released additional data from its Phase II/III trial (study 008A), providing further evidence to support evenamide's potential in schizophrenia. After four weeks of treatment... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| SUPER MICRO COMPUTER | 3.944 |
| EVOTEC | 3.155 |
| TUI | 2.780 |
| NVIDIA | 2.703 |
| BAYER | 2.646 |
| NEL | 2.432 |
| RENK GROUP | 1.777 |
| RHEINMETALL | 1.688 |
| TESLA | 1.285 |
| PALANTIR TECHNOLOGIES | 1.258 |
| VOLKSWAGEN | 1.253 |
| DEUTSCHE BANK | 1.139 |
| PLUG POWER | 1.053 |
| MICROSTRATEGY | 1.035 |
| BYD | 1.033 |
| AMAZON | 1.031 |
| PROSIEBENSAT.1 | 1.019 |
| BASF | 1.014 |
| COMMERZBANK | 1.009 |
| MERCEDES-BENZ | 937 |
| THYSSENKRUPP | 931 |
| ALLIANZ | 878 |
| JINKOSOLAR | 878 |
| DEUTSCHE TELEKOM | 871 |
| AIXTRON SE | 867 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
